Influence of provider factors and race on uptake of breast cancer gene expression profiling-Reference-Cited by-同舟云学术

Influence of provider factors and race on uptake of breast cancer gene expression profiling

Published:2018-01-16 Issue:8 Volume:124 Page:1743-1751
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Reeder-Hayes Katherine E.¹²^ORCID,Wheeler Stephanie B.¹³,Baggett Christopher D.¹⁴,Zhou Xi¹,Meng Ke¹,Roberts Megan C.⁵,Carey Lisa A.¹²,Meyer Anne-Marie¹⁴

Affiliation:

1. Lineberger Comprehensive Cancer Center; University of North Carolina at Chapel Hill; Chapel Hill North Carolina

2. Division of Hematology/Oncology; University of North Carolina at Chapel Hill; Chapel Hill North Carolina

3. Department of Health Policy and Management; University of North Carolina at Chapel Hill; Chapel Hill North Carolina

4. Department of Epidemiology; University of North Carolina at Chapel Hill; Chapel Hill North Carolina

5. Behavioral Research Program, Division of Cancer Control and Population Sciences; National Cancer Institute; Bethesda Maryland

Funder

Conquer Cancer Foundation of the American Society of Clinical Oncology

Susan G. Komen for the Cure

University of North Carolina Breast Cancer Specialized Programs of Research Excellence

Cancer Information and Population Health Resource at the University of North Carolina Lineberger Comprehensive Cancer Center

University Cancer Research Fund via the state of North Carolina

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference30 articles.

1. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer;Paik;N Engl J Med.,2004

2. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20;Tang;Breast Cancer Res Treat.,2011

3. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer;Partin;Ann Surg Oncol.,2011

4. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists;Joh;Oncologist.,2011

5. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer;Albanell;Ann Oncol.,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status;Cancer Epidemiology, Biomarkers & Prevention;2024-01-25

2. From Race to Racism and Disparities to Equity;The Cancer Journal;2023-11

3. Research Silos in Cancer Disparities: Obstacles to Improving Clinical Outcomes for Underserved Patient Populations;Clinical Cancer Research;2023-01-13

4. Understanding Racial and Ethnic Inequities in Uptake and Outcomes Following Multigene Prognostic Testing in Early Breast Cancer: The Promise of Real-World Data;Cancer Epidemiology, Biomarkers & Prevention;2022-04-01

5. Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity;Cancer Epidemiology, Biomarkers & Prevention;2022-01-21